U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H34O8
Molecular Weight 462.5336
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCORTISONE HEMISUCCINATE ANHYDROUS

SMILES

C[C@@]12CCC(=O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@](C(=O)COC(=O)CCC(=O)O)([C@@]4(C)C[C@@]([H])([C@@]31[H])O)O

InChI

InChIKey=VWQWXZAWFPZJDA-CGVGKPPMSA-N
InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H34O8
Molecular Weight 462.5336
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

Curator's Comment:: shown in dogs

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Palliative
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
258 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1162 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
HYDROCORTISONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 4 times / day multiple, intramuscular
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
200 mg 4 times / day multiple, intravenous
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
200 mg 4 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
200 mg single, intravenous
Highest studied dose
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
2.5 % 4 times / day multiple, topical
Dose: 2.5 %, 4 times / day
Route: topical
Route: multiple
Dose: 2.5 %, 4 times / day
Sources:
unhealthy, adult
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Other AEs: Infection...
Other AEs:
Infection (below serious, 6 patients)
Sources:
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Other AEs: Hyperbilirubinemia, Hypertension...
Other AEs:
Hyperbilirubinemia (serious, 1 patient)
Hypertension (serious, 1 patient)
Adrenal insufficiency (serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Infection below serious, 6 patients
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Adrenal insufficiency serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Hyperbilirubinemia serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Hypertension serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Complications of lumbar puncture with injection of hydrosoluble material.
1999 Apr
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.
1999 Apr
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers.
1999 Aug
New weakness in a critically ill patient.
1999 Dec
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
Role of erythropoietin in cortisol-induced hypertension.
2000 Mar
Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure.
2000 Nov
Regulation of interleukin 1 beta RNA expression in the common carp, Cyprinus carpio L.
2001 Apr
Circulatory support of the sick preterm infant.
2001 Feb
Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
2001 Feb
Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.
2001 Feb
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke.
2001 Feb
Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth.
2001 Feb
Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade.
2001 Feb
The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis.
2001 Feb
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
2001 Feb
Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia.
2001 Feb
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
2001 Feb
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
2001 Feb
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.
2001 Feb
Post-dexamethasone cortisol level and memory performance in elderly depressed patients.
2001 Feb 2
Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways.
2001 Jan
Serum allopregnanolone in women with postpartum "blues".
2001 Jan
Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia.
2001 Jan
Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.
2001 Jan
Reference intervals for glucose, beta-cell polypeptides, and counterregulatory factors during prolonged fasting.
2001 Jan
Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus.
2001 Jan
Hydrocortisone abolishes the angiotensin II-mediated potentiation of endothelin-1 in bovine bronchi.
2001 Jan
Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia.
2001 Jan
Neuroendocrine responses to experimentally-induced psychological stress in healthy humans.
2001 Jan
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.
2001 Jan 1
Neural correlates of maternal separation in rhesus monkeys.
2001 Jan 15
Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni.
2001 Jan 15
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:46:41 UTC 2021
Edited
by admin
on Fri Jun 25 20:46:41 UTC 2021
Record UNII
IHV1VP592V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCORTISONE HEMISUCCINATE ANHYDROUS
Common Name English
HYDROCORTISONE HYDROGEN SUCCINATE
WHO-DD  
Common Name English
HYDROCORTISONE HYDROGEN SUCCINATE [WHO-DD]
Common Name English
NSC-7576
Code English
HYDROXYCORTISONE SUCCINATE [INCI]
Common Name English
HYDROXYCORTISONE SUCCINATE
INCI  
INCI  
Official Name English
HYDROCORTISONE HYDROGEN SUCCINATE [EP MONOGRAPH]
Common Name English
CORTISOL SUCCINATE
Common Name English
PREGN-4-ENE-3,20-DIONE, 21-(3-CARBOXY-1-OXOPROPOXY)-11,17-DIHYDROXY-, (11.BETA.)-
Systematic Name English
HYDROCORTISONE SUCCINATE [JAN]
Common Name English
HYDROCORTISONE SUCCINATE
JAN  
Common Name English
ORISTAR HCSHS
Brand Name English
CORTISOL 21-(HYDROGEN SUCCINATE)
Common Name English
Code System Code Type Description
PUBCHEM
16623
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL977
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
CAS
2203-97-6
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
FDA UNII
IHV1VP592V
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
ECHA (EC/EINECS)
218-612-3
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
DRUG CENTRAL
4456
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
DRUG BANK
DB14545
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
RXCUI
21651
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY RxNorm
EVMPD
SUB22787
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
EPA CompTox
2203-97-6
Created by admin on Fri Jun 25 20:46:41 UTC 2021 , Edited by admin on Fri Jun 25 20:46:41 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY